Anika Therapeutics (ANIK) Gains from Sales and Divestitures (2011 - 2026)
Anika Therapeutics (ANIK) reported Gains from Sales and Divestitures of $310370.0 for Q1 2026, up 24.06% year-over-year from $250172.0 in Q1 2025, and down 2.35% quarter-over-quarter from $317850.0 in Q4 2025.
Anika Therapeutics (ANIK) Gains from Sales and Divestitures (2011 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 15 years of Gains from Sales and Divestitures data on file, last reported at $310370.0 in Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $310370.0, up 24.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $310370.0 (up 24.06% YoY), and the FY2025 annual result was $317850.0, up 2.06% from the prior year.
- Gains from Sales and Divestitures fell to $310370.0 in Q1 2026 per ANIK's latest filing, from $317850.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $317850.0 in Q4 2025 and troughed at $19125.0 in Q2 2022.
- A 5-year average of $212820.2 and a median of $250172.0 in 2025 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2022 and 2023: Gains from Sales and Divestitures slumped 79.14% in 2022, then soared 1254.95% in 2023.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $19125.0 in 2022, then soared by 1254.95% to $259134.0 in 2023, then gained by 20.19% to $311441.0 in 2024, then gained by 2.06% to $317850.0 in 2025, then retreated by 2.35% to $310370.0 in 2026.
- Business Quant data shows ANIK's Gains from Sales and Divestitures at $310370.0 in Q1 2026, $317850.0 in Q4 2025, and $316105.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Anika Therapeutics | 200.80 Mn | 134.01 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 310,370.00 |
| Mar 31, 2026 | 310,370.00 |
| Dec 31, 2025 | 317,850.00 |
| Dec 31, 2025 | 317,850.00 |
| Jun 30, 2025 | 316,105.00 |
| Jun 30, 2025 | 316,105.00 |
| Mar 31, 2025 | 250,172.00 |
| Mar 31, 2025 | 250,172.00 |
| Dec 31, 2024 | 311,441.00 |
| Dec 31, 2024 | 311,441.00 |
| Sep 30, 2024 | 308,634.00 |
| Sep 30, 2024 | 308,634.00 |
| Jun 30, 2024 | 298,573.00 |
| Jun 30, 2024 | 298,573.00 |
| Mar 31, 2024 | 249,716.00 |
| Mar 31, 2024 | 249,716.00 |
| Sep 30, 2023 | 259,134.00 |
| Sep 30, 2023 | 259,134.00 |
| Jun 30, 2023 | 247,369.00 |
| Jun 30, 2023 | 247,369.00 |